Grifols Invests in Sterile Manufacturing
Part of the special news roundup of DCAT member companies for the DCAT Week ’17 Special Edition of DCAT Value Chain Insights (April 5, 2017)
Grifols, a Barcelona, Spain-headquartered healthcare company specializing in plasma-derived proteins and contract manufacturer of sterile solutions, recently has made investments in sterile manufacturing technology with the installation of a fourth form/fill/ seal (FFS) line in its manufacturing site in Murcia, Spain. The addition of the new FFS line will increase the company’s flexible bag manufacturing capacity by 30%. The new line can operate using the standard Grifols connector and can also manufacture bags with one or two tubes.
The new line will be operational in 2017 once validations have been completed and approved by Spanish health authorities. Grifols is also waiting for US Food and Drug Administration approval for the new FFS line as part of the company’s plan to expand sales of parenteral solutions in new markets. The Murcia facility has also been fitted with a new high-capacity autoclave and a new conditioning line to handle the increased production.
Another production line is scheduled to be completed in the company’s Parets del Vallés facility in Barcelona, in the first half of 2018.